Indications and uses
To relieve the symptoms of fainting.
To relieve the symptoms of fainting.
Adults: Dissolve 3 to 5 under the tongue three times a day or as directed by Lic. Practitioner. Take at greater intervals as condition subsides. Children: Dissolve 3 to 5 under the tongue three times a day or as directed by Lic. Practitioner. Take at greater intervals as condition subsides.
AMMON BROM 30C
To relieve the symptoms of fainting.
Keep this and all medicines out of reach of children.
Indications:
AMMON BROM Dry cough
If symptoms persist/worsen or if pregnant/nursing, stop use and consult your practitioner.
Adults: Dissolve 3 to 5 under the tongue three times a day or as directed by Lic. Practitioner. Take at greater intervals as condition subsides. Children: Dissolve 3 to 5 under the tongue three times a day or as directed by Lic. Practitioner. Take at greater intervals as condition subsides.
Sucrose/Lactose
The OTC potency range of AMMON BROM is 2x–30x, 1c–30c, 200c, 1m, 10m, 50m, and CM.
Availability is subject to change.
All WHP single remedies are made to order; thus, the labels are printed on the same label stock as the orders are filled.
‘Bottle Size’ and ‘Potency’ vary on the label depending on customer choice.
Standard bottle sizes for pellet-form remedies are 2 dram, 4 dram, 1 ounce, 2 ounce, and 4 ounce.
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 68428-877 | 68428-877-03, 68428-877-05, 68428-877-11, 68428-877-12, 68428-877-06 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| SUCROSE | C151H8M554 | IACT |
| LACTOSE | J2B2A4N98G | IACT |
| AMMONIUM BROMIDE | R0JB3224WS | ACTIB |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| db856a1f-b0f4-e458-e053-2995a90a7bcf | ba26d2c7-9f16-4cd3-b1ed-e037ec014f36 | 2022-03-31 | Warnings | ba26d2c7-9f16-4cd3-b1ed-e037ec014f36 |
Adverse event summaries are temporarily unavailable. Other product information remains available.